Applied Therapeutics, Inc. (APLT) News
Filter APLT News Items
APLT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest APLT News From Around the Web
Below are the latest news stories about APPLIED THERAPEUTICS INC that investors may wish to consider to help them evaluate APLT as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! |
Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in EuropeAdvanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD DeficiencyApplied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net sales in Europe Deal strengthens Applied Therapeutics’ capital position and extends cash runway through key milestones NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-sta |
Applied Therapeutics Reports Third Quarter 2022 Financial ResultsNEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In the third quarter, we made significant progress across all three of our late-stage programs,” said Shoshana Shendelman, PhD, Founder, CEO and C |
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as an important metric of quality of life and physical functioning in Diabetic Cardiomyopathy patients NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical |
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic CardiomyopathyARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placeboPrimary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 monthsDbCM is a form of heart failure affecting approximately 20% of Type 2 Diabetes patients (~6M patients in the US and ~5M in EU), which represents a significant commercial market opportunityThere are currently no treatme |
Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62The recent price decline of 33% in Applied Therapeutics, Inc.'s ( NASDAQ:APLT ) stock may have disappointed insiders... |
Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical SignificanceApplied Therapeutics Inc's (NASDAQ: APLT) ACTION-Galactosemia Kids Phase 3 trial has demonstrated a trend in clinical benefit favoring AT-007 vs. placebo. The study is designed to evaluate the impact of AT-007 vs. placebo on clinical outcomes in children with Classic Galactosemia, with a review of safety and efficacy every six months. Classic galactosemia is an inherited condition in which the body cannot properly digest galactose, a sugar found in all foods containing milk. The sugar buildup ca |
Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format• The study did not yet reach statistical significance at 12 months of treatment; however, AT-007 (gavorostat) demonstrated a trend in clinical benefit vs. placebo• Applied Therapeutics plans to meet with the EMA to discuss potential submission of the current data package for conditional approval in the EU• Trial will continue to 18 months in blinded format NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing |
Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' NowAfter losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving! |